SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 73 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $13,000 | +18.2% | 1,423 | -45.9% | 0.00% | – |
| Q1 2019 | $11,000 | 0.0% | 2,628 | 0.0% | 0.00% | – |
| Q4 2018 | $11,000 | -42.1% | 2,628 | +10.1% | 0.00% | -100.0% |
| Q3 2018 | $19,000 | -17.4% | 2,388 | -26.7% | 0.00% | -50.0% |
| Q2 2018 | $23,000 | -51.1% | 3,256 | -0.8% | 0.00% | – |
| Q1 2018 | $47,000 | +487.5% | 3,281 | +244.6% | 0.00% | – |
| Q4 2017 | $8,000 | -71.4% | 952 | +27.3% | 0.00% | -100.0% |
| Q3 2017 | $28,000 | -24.3% | 748 | -71.7% | 0.00% | -50.0% |
| Q2 2017 | $37,000 | +825.0% | 2,641 | +911.9% | 0.00% | – |
| Q1 2017 | $4,000 | – | 261 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |